Modalis Therapeutics Corporation (4883.T)
JPY 77.0
(-1.28%)
JPY 77.0
(-1.28%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.37 Billion JPY | -48.41% |
| 2022 | -2.58 Billion JPY | -37.47% |
| 2021 | -667.54 Million JPY | -201.14% |
| 2020 | -381.96 Million JPY | -3083.01% |
| 2019 | - JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -456.41 Million JPY | 43.61% |
| 2024 Q2 | -348.86 Million JPY | 29.55% |
| 2023 Q1 | -508.79 Million JPY | 14.01% |
| 2023 Q4 | -807.82 Million JPY | -47.88% |
| 2023 Q3 | -546.28 Million JPY | -12.76% |
| 2023 FY | - JPY | -48.41% |
| 2023 Q2 | -484.46 Million JPY | 4.78% |
| 2022 Q3 | -537.72 Million JPY | 0.0% |
| 2022 FY | - JPY | -37.47% |
| 2022 Q4 | -591.69 Million JPY | -10.04% |
| 2021 FY | - JPY | -201.14% |
| 2020 FY | - JPY | -3083.01% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | 139.427% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 100.271% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 99.155% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 101.272% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | 515.769% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 106.542% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | 119.352% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 102.302% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | 283.598% |
| Hisamitsu Pharmaceutical Co., Inc. | 18.34 Billion JPY | 112.944% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | 126.456% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | 164.685% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | 269.203% |
| Tsumura & Co. | 30.77 Billion JPY | 107.715% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 112.681% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | 145.037% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 106.68% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | 134.495% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | 113.549% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | 123.057% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 36.695% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | 131.43% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | -232.482% |
| MedRx Co., Ltd | -884.51 Million JPY | -168.387% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | 142.879% |
| Solasia Pharma K.K. | -635 Million JPY | -273.846% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | 125.908% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 106.438% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | -341.013% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 109.185% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | 146.533% |